Articles with public access mandates - Laura de-la-Puente-Ovejero (ORCID 0000-0002-0835-7069)Learn more
Available somewhere: 4
An overview of alternative splicing defects implicated in myotonic dystrophy type I
A López-Martínez, P Soblechero-Martín, L de-la-Puente-Ovejero, ...
Genes 11 (9), 1109, 2020
Mandates: Government of Spain
Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies
P Soblechero‐Martín, A López‐Martínez, L de la Puente‐Ovejero, ...
Neuropathology and Applied Neurobiology 47 (6), 711-723, 2021
Mandates: Government of Spain
Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation
S García-Alonso, P Mesa, L de la Puente Ovejero, G Aizpurua, ...
Molecular cell 82 (18), 3438-3452. e8, 2022
Mandates: European Commission, Government of Spain, AXA Research Fund, France
Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening
P Soblechero-Martín, E Albiasu-Arteta, A Anton-Martinez, ...
Scientific Reports 11 (1), 18188, 2021
Mandates: Government of Spain
Publication and funding information is determined automatically by a computer program